After looking at the results Novo Nordisk released this morning we’re beginning to think their corporate communication team is going to need a class in creative writing. Look at this passage from this morning’s earnings release;
“Sales of insulin in North America Operations decreased by 17% in Danish kroner and by 7% in local currencies. The decline in sales in the USA in the basal insulin segment was mainly driven by lower realised prices for Levemir® and phasing of rebates in 2017 for Tresiba® partly offset by higher sales of Tresiba® following a net market share gain of . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.